Key facts
- Australia's TGA approved Iovance Biotherapeutics' Amtagvi.
- The drug is for adult patients with unresectable or metastatic melanoma.
- This is the first approval for Amtagvi in Australia.
The Therapeutic Goods Administration (TGA) in Australia has granted approval for Iovance Biotherapeutics' drug, Amtagvi. This approval is specifically for adult patients diagnosed with unresectable or metastatic melanoma. Amtagvi represents a new treatment option for this patient population in Australia, marking its first regulatory clearance in the country.